Vitamin B1 · Benfotiamine · Nerve & Metabolic Health
Benfotiamine: Benefits, Dosage, Side Effects, and What the Neuropathy Evidence Shows
Benfotiamine is a fat-soluble form of vitamin B1 that gets thiamine into the body far better than the ordinary vitamin, and it works on the same sugar-damage pathways that injure nerves in diabetes.
The Short Version
Benfotiamine is a fat-soluble form of vitamin B1 that raises thiamine levels in the blood far more than ordinary thiamine does. Its best-studied use is diabetic neuropathy: in placebo-controlled trials, 300 to 600 mg a day improved symptoms, especially pain, within three to six weeks. Longer trials have been mixed. It has been well tolerated in trials, with side effects similar to placebo. It supports nerve health; it doesn't replace blood sugar control.
Dr. Michael Fitzmaurice
Peripheral Nerve Surgeon & Metabolic Health Educator
"In the operating room, a diabetic nerve looked different. It was often swollen, the tissue around it stiffer, and it recovered more slowly after I released it. Glucose had been damaging that nerve for years before I ever saw it. Benfotiamine interested me because it doesn't just add a vitamin. It gives the cell another way to dispose of the excess sugar that drives the damage."
Most people meet benfotiamine on a supplement label and assume it's just a fancy name for vitamin B1. It isn't, and the difference is the reason it has been studied in diabetic neuropathy for more than two decades.
Ordinary thiamine is water-soluble. It's absorbed through a transporter that saturates quickly, and whatever the body can't use is flushed out in the urine. That ceiling matters in diabetes, where the kidneys clear thiamine far faster than normal. Benfotiamine is a fat-soluble precursor of thiamine. It is absorbed far more completely, and once inside the body it's converted to the active coenzyme cells actually use. Same vitamin, very different delivery.
This guide covers what benfotiamine is, which benefits human studies actually support (and which ones they don't yet), how it compares with other forms of B1, the doses studied, side effects, and what the neuropathy trials found. I've organized the benefits by strength of evidence, because the honest answer to "what does benfotiamine do?" depends on which question you're asking.
What You'll Learn
➤ What benfotiamine is, and how it differs from thiamine and other B1 forms
➤ The transketolase mechanism: how it diverts glucose away from nerve-damaging pathways
➤ Benfotiamine benefits ranked by strength of evidence, from neuropathy to memory
➤ What the BEDIP, BENDIP and BOND neuropathy trials found
➤ Benfotiamine dosage: how much per day, with or without food, and for how long
➤ Side effects, safety, and how to combine it with alpha-lipoic acid and B12
What Is Benfotiamine?
Benfotiamine is a synthetic, fat-soluble precursor of thiamine (vitamin B1). Japanese researchers first described it in 1961 as part of a broader effort to build forms of B1 the body could absorb more completely. Chemically it's an S-acyl derivative (thiamine with a chemical side group attached that makes it fat-soluble), which is what sets it apart from the thiamine in a typical multivitamin.
After you swallow it, enzymes in the gut wall strip off its phosphate group, the remaining molecule is absorbed, and the body then converts it to ordinary thiamine. From there it becomes thiamine diphosphate, the active coenzyme that glucose-processing enzymes depend on. In other words, benfotiamine ends up as the same molecule your cells already use. What changes is how much of it gets in.
In the US, benfotiamine is sold as a dietary supplement, most often in 150 mg and 300 mg capsules. In parts of Europe it has a different status: it has been licensed as a medicine in Germany for more than a decade, and Swiss regulators authorized a 300 mg benfotiamine medicine in 2023 for conditions that respond to vitamin B1, including diabetic and alcoholic polyneuropathy.
Why Thiamine Matters So Much for Diabetic Nerves
Thiamine (vitamin B1) is the helper molecule for several enzymes at the heart of glucose metabolism. Its active form, thiamine diphosphate, is needed to move glucose into the mitochondria for energy and to run the pentose phosphate pathway, a side route for processing sugar. Nerve cells burn glucose constantly and have little stored energy, so they feel a thiamine shortfall early. Severe deficiency causes beriberi, which includes a painful peripheral neuropathy.
Here is the part most people don't know: low thiamine is common in diabetes, even in people who eat well. In one study, plasma thiamine was about 75% lower in people with type 1 and type 2 diabetes than in healthy volunteers, because the kidneys were clearing it 16 to 24 times faster than normal. Standard blood tests can miss this, which the same study also showed. So the people who most need thiamine's glucose-handling help are often the ones running shortest on it.
✦ KEY TAKEAWAY
Diabetes drains thiamine through the kidneys at the same time it increases the glucose load that thiamine-dependent enzymes have to handle. Benfotiamine was developed to get thiamine into the body more effectively than the ordinary vitamin can.
Get the Free Nerve Health Blueprint
The nutrition, lifestyle and testing framework I used with patients over 20+ years as a peripheral nerve surgeon, in one free guide.
Get the Free Blueprint →How Benfotiamine Works: The Transketolase Mechanism
When blood sugar runs high, cells take in more glucose than their main energy pathway can process. The overflow backs up as two intermediate molecules, glyceraldehyde-3-phosphate and fructose-6-phosphate. Those backed-up molecules feed the pathways that do the damage in diabetic complications: the formation of advanced glycation end-products (AGEs, proteins stiffened and damaged by sugar), the hexosamine pathway, and protein kinase C activation, which disrupts the small blood vessels that feed nerves. I explain how those pathways injure nerves in how high blood sugar damages nerves.
Benfotiamine's job is to open a drain. It boosts the activity of transketolase, a thiamine-dependent enzyme that converts those two backed-up intermediates into harmless five-carbon sugars in the pentose phosphate pathway. In a landmark 2003 study in Nature Medicine, Hammes, Brownlee and colleagues showed that benfotiamine blocked three major pathways of hyperglycemic damage at once by activating transketolase, and prevented diabetic damage to the retina in animals. Blocking three pathways with one mechanism is unusual, and it's the reason benfotiamine became a serious candidate for diabetic nerve damage.
From a surgeon's point of view, this is the appeal. Most nerve supplements support the nerve. Benfotiamine works upstream, on the metabolic traffic jam that injures the nerve in the first place.
Benfotiamine Benefits: What Human Studies Support
Search for benfotiamine benefits and you'll find lists that put diabetic neuropathy, memory, kidney protection and "anti-aging" side by side, as if the evidence were equal. It isn't. A mechanism shown in a dish or a mouse is a reason to run a human trial, not a result. Here is how the benefits sort out when you rank them by the quality of the human evidence behind them.
| Use | Evidence | What was found |
|---|---|---|
| Diabetic neuropathy symptoms | Placebo-controlled trials (BEDIP, BENDIP); mixed longer trials | Symptom and pain improvement at 3 to 6 weeks; the 12-month BOND trial was inconclusive, since participants had little room to improve |
| Raising thiamine levels | Absorption studies in healthy volunteers | Much higher blood thiamine than thiamine HCl |
| Thiamine status in diabetes | Observational | Plasma thiamine about 75% lower in diabetes |
| Memory and cognition | One small phase IIa trial | Primary outcome not significant; being studied, not established |
| Alcohol use | One trial | Drinking fell in both groups; early, not established |
| Diabetic eye and kidney damage, AGEs | Animal and lab studies | Strong mechanism; not shown in human outcomes |
Neuropathy is where the human evidence is strongest, and I cover those trials in detail in the next section. The absorption data are solid too: benfotiamine reliably raises thiamine levels far more than the ordinary vitamin, which I'll quantify in the comparison section below.
Memory and Cognition: Being Studied, Not Established
Because thiamine-dependent enzymes also run brain glucose metabolism, researchers have asked whether benfotiamine could slow cognitive decline. The best human data so far come from a single phase IIa trial. Gibson and colleagues gave 70 people with mild cognitive impairment or mild Alzheimer's disease either 600 mg of benfotiamine a day (300 mg twice daily) or placebo for 12 months. The primary cognitive measure, the ADAS-Cog, declined 43% less on benfotiamine, but that difference was not statistically significant (p = 0.125). A secondary clinical rating, the CDR, worsened 77% less (p = 0.034). A larger trial in about 400 people, BenfoTeam (NCT06223360), is now testing 600 and 1,200 mg a day over 72 weeks. Until it reports, the accurate summary is that benfotiamine is being studied for cognition. It is not an established treatment for memory loss.
Alcohol Use: One Trial
Alcohol is one of the most reliable ways to drain thiamine, which is why benfotiamine has been studied in people who drink heavily. In one trial, Manzardo and colleagues gave 120 adults with alcohol dependence 600 mg a day or placebo for 24 weeks. Drinking fell in both groups. Among the 21 women who completed the trial, the reduction was greater on benfotiamine, and the supplement was well tolerated. That is a single trial with a small subgroup finding, so it can't support a benefit claim. The more practical point is the one in the practical tool below: if you drink regularly and have nerve symptoms, your thiamine status deserves attention.
Benfotiamine for Neuropathy: What the Clinical Trials Show
Benfotiamine's human evidence comes mainly from placebo-controlled trials in people with diabetic polyneuropathy, the stocking-glove pattern of burning, tingling, and numbness that starts in the feet. Two short trials form the core of it.
BEDIP: Pain Relief Within Three Weeks
The BEDIP study randomized 40 people with type 1 or type 2 diabetes and neuropathy of less than two years' duration to benfotiamine (400 mg a day) or placebo. After just three weeks, the benfotiamine group had a statistically significant improvement in neuropathy scores compared with placebo, and pain was the symptom that improved most. The improvement was not explained by better blood sugar, since HbA1c didn't change. No side effects attributable to benfotiamine were seen.
BENDIP: A Larger Effect at the Higher Dose
The larger BENDIP trial randomized 165 people with diabetic polyneuropathy to 600 mg a day, 300 mg a day, or placebo for six weeks. The main outcome, the Neuropathy Symptom Score, improved significantly with benfotiamine in patients who completed the study as designed (and was just short of significance when every enrolled patient was counted). Three findings stand out. The improvement was more pronounced at 600 mg than at 300 mg, it grew the longer people took it, and pain was again the symptom that responded best. Treatment was well tolerated in all groups.
A larger effect at the higher dose and a benefit that builds over time are encouraging signs. Still, that comes from one six-week trial, so it isn't a formal dose-response finding.
What the Meta-Analyses Add
Pooled analyses point the same way. A 2021 systematic review in the European Journal of Neurology found that vitamin B1 treatment was associated with symptom improvement in peripheral neuropathy. A 2026 meta-analysis of 13 randomized trials found that B-vitamin treatment improved neuropathy scores and sural nerve conduction in diabetic neuropathy, and that combinations of B vitamins looked more promising than single vitamins. A 2023 review by the leading diabetic neuropathy researcher Dan Ziegler listed benfotiamine among the pathogenesis-oriented treatments with demonstrated efficacy and excellent safety in randomized trials.

Reading the Longer Trials in Context
The longest neuropathy trial so far, BOND, gave 57 people with type 2 diabetes and mild-to-moderate neuropathy 600 mg a day for 12 months and found no significant effect on nerve structure, nerve testing, or quality of life. That result is easy to over-read. Participants started with very little pain (average daily pain of about 1 to 2 out of 10), almost none were low in thiamine, and nerve function didn't worsen in the placebo group over the year. That left little room for either group to improve, and the authors acknowledge these limits. The one symptom score that did have room to move was also the one that trended in benfotiamine's favor. A trial set up this way can't tell us whether benfotiamine works; it neither confirms nor rules out a benefit. An earlier two-year study gave 67 people with type 1 diabetes 300 mg a day, enrolled for their diabetes rather than for neuropathy symptoms. Their blood thiamine rose sharply, but nerve function did not change compared with placebo. Shorter trials in people with more active symptoms were positive, so benfotiamine appears more likely to ease symptoms than to change nerve structure.
The bigger lesson is about single-ingredient trials. Nerves fail through several pathways at once, so a study that tests one nutrient alone can underestimate what that nutrient contributes to a broader plan. That's consistent with the meta-analysis finding that B-vitamin combinations outperform single vitamins.
✦ KEY TAKEAWAY
In people with symptomatic diabetic neuropathy, benfotiamine improved symptoms (especially pain) within three to six weeks, with a larger effect at 600 mg than 300 mg in BENDIP. The effect is real but modest, it hasn't been shown to change nerve structure, and it shows up best in people with active symptoms and as part of a combination approach.
Why I formulated NeuroAxis
The trials point to combinations rather than any single vitamin. Nerves depend on several nutritional pathways at once: energy production, antioxidant defense, and myelin support. NeuroAxis combines 300 mg of benfotiamine with methylcobalamin, R-alpha-lipoic acid, and other researched nutrients in a single multi-pathway formula.*
Every order also includes the 160-page NeuroAxis Protocol, my guide to the nutrition and lifestyle pillars that come before any supplement.
See NeuroAxis + the 160-Page Protocol →*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Benfotiamine vs Thiamine (and Other B1 Forms)
All of these forms deliver the same vitamin. The differences are in how much of it gets absorbed and how much human research sits behind each one. Ordinary thiamine, sold as thiamine hydrochloride (HCl) or thiamine mononitrate, is what you'll find in most multivitamins. It's water-soluble and enters the body through a transporter in the gut that saturates at fairly low intakes, so taking more yields diminishing returns and the excess is cleared in the urine.
Benfotiamine gets around that bottleneck. In a study of healthy volunteers, Xie and colleagues found that benfotiamine produced about 11 times the plasma thiamine exposure of thiamine HCl and about twice the red blood cell thiamine diphosphate. That second number matters most, because thiamine diphosphate is the form enzymes actually use. The other fat-soluble forms, allithiamine and its relatives, belong to a different chemical family (the disulfides). One of them, fursultiamine, gave similar total thiamine exposure to benfotiamine in a crossover study, but these forms have little neuropathy trial data.
| Form | Type | Key point |
|---|---|---|
| Thiamine HCl / thiamine mononitrate | Water-soluble (most multivitamins) | Absorbed through a transporter that saturates; excess cleared in urine |
| Benfotiamine | Fat-soluble S-acyl precursor | About 11 times the plasma thiamine and twice the red-cell thiamine diphosphate of thiamine HCl; the form used in most neuropathy trials |
| Allithiamine / TTFD / fursultiamine | Fat-soluble disulfide derivatives | Fursultiamine matched benfotiamine's total thiamine exposure in one crossover study; little neuropathy trial data |
| Sulbutiamine | Fat-soluble disulfide derivative | Marketed for energy and focus; one small, unblinded neuropathy study |
Sulbutiamine deserves a sentence of its own, because it's often sold as a "brain" form of B1. Its neuropathy research amounts to one small, open-label study of 30 people with type 2 diabetes: after six weeks, nerve conduction improved, but symptom scores did not differ from untreated controls. That's a reason for more study, not a reason to choose it.
So which form should you use? For simply correcting low intake, ordinary thiamine works, and it's in nearly every multivitamin. For the nerve question, benfotiamine is the form with the placebo-controlled trials. That distinction shows up on real labels: Nervive's tablets, for example, use thiamin mononitrate rather than benfotiamine, which I break down in my Nervive review.

Water-soluble thiamine relies on a gut transporter that saturates; fat-soluble benfotiamine is absorbed far more completely before being converted to thiamine.
Benfotiamine Dosage: How Much Per Day?
The neuropathy trials used 300 to 600 mg a day, usually split into two or more doses. BEDIP used 400 mg a day; BENDIP compared 300 mg with 600 mg and found the larger effect at 600 mg. Symptom changes appeared at three to six weeks, but because nerves recover slowly, I'd judge any nerve support plan over about 90 days rather than a few weeks. My guide to how long nerve supplements take to work explains what to track in the meantime.
Across the human research, the doses fall into a narrow band:
- Neuropathy: 300 to 600 mg a day (BEDIP 400 mg; BENDIP 300 vs 600 mg; BOND 600 mg)
- Alcohol trial: 600 mg once a day
- Cognition: 600 mg a day in the phase IIa trial, with 600 vs 1,200 mg now being tested in BenfoTeam
- Common supplement doses: 150 to 300 mg, once or twice daily
Dose matters when you compare products. Nerve Renew, for instance, recently cut its benfotiamine from 600 to 300 mg; my Nerve Renew review looks at what BENDIP actually found about those two doses.
Is there an upper limit? The US National Academies found too little evidence of harm to set a tolerable upper intake level for thiamine. That isn't a license for unlimited doses. The trials mostly stayed at or below 600 mg a day, and that's the range with safety data behind it.
With or without food? Benfotiamine is fat-soluble, and many products advise taking it with a meal. No trial has compared the two, so taking it with food is a reasonable practice rather than a proven requirement. Splitting the dose (morning and evening) mirrors how most of the neuropathy trials gave it.
Prefer benfotiamine on its own?
I carry a single-ingredient 300 mg benfotiamine capsule from NusaPure, made with BioPerine. One capsule matches the dose in BENDIP's lower arm, and it's the same benfotiamine dose that's in NeuroAxis. Two capsules give 600 mg, the dose with the larger effect in BENDIP; confirm the dose with your clinician. Benfotiamine supports healthy thiamine levels and normal energy metabolism.* BioPerine (black pepper extract) can change how some medications are absorbed, so review it with your clinician if you take prescription drugs.
"I'm a believer in the research supporting combination formulas, which is why NeuroAxis exists. But some people just want a single ingredient. When I find a quality single-ingredient product already on the market, I'd rather carry it than put my own label on it."
See Benfotiamine 300 mg →*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Benfotiamine Side Effects and Safety
In the controlled trials, benfotiamine's side-effect profile looked like placebo. BEDIP saw no side effects attributable to benfotiamine, BENDIP reported it was well tolerated at both doses, and BOND found no relevant differences in adverse events between benfotiamine and placebo over 12 months at 600 mg a day. The Alzheimer's trial reported no adverse events related to 600 mg a day over a year, and the alcohol trial found it well tolerated over 24 weeks. Across these studies, no consistent side-effect pattern has emerged.
What hasn't been well studied matters just as much. There are few data on benfotiamine in pregnancy or breastfeeding, in children, or for use beyond 12 months. No well-documented drug interactions have been reported, but if you take several medications, have kidney disease, or have surgery coming up, review every supplement with your clinician first.
Does benfotiamine cause hair loss? There is no clinical evidence that benfotiamine causes or prevents hair loss.
The one real safety trap is in combination products. Many "nerve" formulas pair benfotiamine with vitamin B6, and B6 is the one nerve vitamin where too much can itself cause neuropathy. I cover that in the combinations section below and in my vitamin B6 and neuropathy guide.
✦ Practical Tool: Is Benfotiamine Worth Trying?
Benfotiamine is most likely to be worth a trial if several of these apply:
1. You have diabetes or prediabetes, and your symptoms fit a stocking-glove pattern.
2. Burning or pain is a main complaint, not only numbness.
3. You drink alcohol regularly, have had bariatric surgery, or eat a very restricted diet (all thiamine drains).
4. You're working on blood sugar at the same time, so the supplement isn't fighting an active current alone.
It's less likely to help a nerve being mechanically compressed, such as in carpal tunnel syndrome. That needs the pressure taken off.
Benfotiamine With Alpha-Lipoic Acid, Methylcobalamin and Other Nutrients
Benfotiamine handles the metabolic side of nerve stress. It doesn't build myelin or neutralize free radicals directly, which is why it's usually paired with other nutrients. Methylcobalamin, the active form of vitamin B12, supports the myelin sheath and the Schwann cells that maintain it, and it matters most when B12 is low, as it often is with long-term metformin. I cover it in depth in methylcobalamin for nerve repair.
Benfotiamine and Alpha-Lipoic Acid
Benfotiamine and alpha-lipoic acid are paired so often because they work on different pathways. Benfotiamine reroutes the glucose overflow that feeds AGE formation. Alpha-lipoic acid is an antioxidant that counters the oxidative stress downstream, and it has the strongest trial record of any single supplement in diabetic neuropathy. The honest caveat is that most trials tested each one alone. The 2026 meta-analysis that favored combinations looked at combinations of B vitamins, not B vitamins plus alpha-lipoic acid, so the case for pairing these two rests on their separate evidence and complementary mechanisms rather than on head-to-head combination trials. If you're comparing finished nerve formulas, my audit of seven popular neuropathy supplements shows how their doses line up with the trials.
Watch the B6
One caution if you're building your own combination: many B-complex and "nerve" products also contain vitamin B6, and B6 is the one nerve vitamin where too much causes neuropathy. Add up the B6 across everything you take; my vitamin B6 and neuropathy guide explains the limits. For the full ranking of nerve vitamins, see my hub guide to vitamins for neuropathy.
That combination logic is how I built NeuroAxis, a nerve support supplement that pairs 300 mg of benfotiamine (the dose of BENDIP's lower arm) with 2,000 mcg of methylcobalamin and 600 mg of R-alpha-lipoic acid. NeuroAxis contains 10 mg of vitamin B6, below the US (100 mg), Australian (50 mg) and European (12 mg) daily upper limits. B6 risk is cumulative across everything you take, so check the B6 in any other supplements too. Read more about B6 and nerves. In the interest of full disclosure, I developed the formula and am the senior author on the published research behind it.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Putting It Into Practice
Today
Write down your baseline: how often symptoms occur, how many nights they disturb sleep, and how far you can walk comfortably. List every supplement you take, with doses.
This Week
Talk with your clinician about the cause of your neuropathy and ask for B12, vitamin D, and an A1C if they haven't been checked recently.
This Month
If you start benfotiamine, take it consistently at a studied dose and pair it with the blood sugar work. Pain and burning are the symptoms most likely to shift first.
Long Term
Reassess against your baseline at about 90 days. If nothing has moved, revisit the diagnosis and the plan rather than simply adding more supplements.
See a clinician promptly, rather than waiting, for rapidly worsening symptoms, new weakness, falls, or symptoms on one side only.
Frequently Asked Questions
What are the benefits of benfotiamine?
The best-supported benefit is relief of diabetic neuropathy symptoms, especially pain: placebo-controlled trials found improvement within three to six weeks at 300 to 600 mg a day, though a 12-month trial in people with little pain and normal thiamine levels couldn't show an effect on nerve structure. Benfotiamine also reliably raises thiamine levels far more than ordinary thiamine. Benefits for memory and alcohol use have each been tested in a single trial and are not established, and protection of the eyes and kidneys has been shown only in animal and lab studies.
Does benfotiamine help neuropathy?
In placebo-controlled trials of people with diabetic polyneuropathy, benfotiamine improved neuropathy symptoms within three to six weeks, with pain improving most, and the BENDIP trial saw a larger effect at 600 mg a day than at 300 mg. The 12-month BOND trial found no significant effect on nerve structure or testing, but its participants had little pain, normal thiamine levels, and nerves that didn't worsen on placebo, which left little room to show a benefit either way. It works best alongside blood sugar control and other nerve-support nutrients.
Is benfotiamine the same as vitamin B1?
It's a form of vitamin B1 that the body converts to thiamine. Benfotiamine is a synthetic, fat-soluble precursor: once absorbed, it becomes ordinary thiamine and then thiamine diphosphate, the active coenzyme cells use. The difference is delivery, since benfotiamine raises blood thiamine far more than the same amount of standard thiamine.
What is the difference between benfotiamine and thiamine?
Both supply vitamin B1. Ordinary thiamine is water-soluble and absorbed through a transporter that saturates quickly. Benfotiamine is fat-soluble and absorbed far more completely; in healthy volunteers it produced about 11 times the plasma thiamine and twice the red blood cell thiamine diphosphate of thiamine HCl. Most of the neuropathy trials used benfotiamine.
How does benfotiamine work?
Benfotiamine activates transketolase, a thiamine-dependent enzyme that converts excess glucose intermediates into harmless sugars. That diverts them away from three pathways that damage nerves and blood vessels in diabetes: advanced glycation end-product formation, the hexosamine pathway, and protein kinase C activation.
How much benfotiamine should I take per day?
The neuropathy trials studied 300 to 600 mg a day, usually in divided doses, and the larger effect was seen at 600 mg. Common supplements provide 150 to 300 mg once or twice daily. No upper intake limit has been set for thiamine, but the trials mostly stayed at or below 600 mg a day. Talk with your clinician about the right dose for you, especially if you take prescription medications.
Should benfotiamine be taken with food?
Benfotiamine is fat-soluble, and many products advise taking it with a meal. No trial has compared taking it with or without food, so taking it with a meal is a reasonable practice rather than a proven requirement. Most neuropathy trials split the daily dose into morning and evening.
How long does benfotiamine take to work?
In trials, symptom improvements appeared at three to six weeks and grew with longer treatment. Because nerves recover slowly, plan on about 90 days of consistent use before judging whether it's helping.
What are the side effects of benfotiamine?
In placebo-controlled trials lasting up to 12 months at doses up to 600 mg a day, side effects were similar to placebo, and the trials have not identified a consistent side-effect pattern. It has not been well studied in pregnancy, breastfeeding, children, or for use beyond 12 months.
Is benfotiamine safe?
Benfotiamine has been well tolerated in clinical trials of up to 12 months, with adverse events no different from placebo. Long-term safety beyond a year, and use in pregnancy, breastfeeding and children, have not been well studied. Check with your physician before starting it if you take prescription medications, have kidney disease, have surgery planned, or are pregnant or breastfeeding.
Does benfotiamine cause hair loss?
There is no clinical evidence that benfotiamine causes or prevents hair loss.
Can I take benfotiamine with methylcobalamin?
Yes. They work on different pathways, benfotiamine on glucose-driven metabolic stress and methylcobalamin on myelin support, and research suggests combinations of B vitamins may be more effective than single vitamins. If you combine products, add up the vitamin B6 across all of them, since too much B6 can itself cause neuropathy.
Where to go from here
Explore NeuroAxis: the multi-pathway nerve support formula I developed, with the 160-page NeuroAxis Protocol included.*
Get the free Nerve Health Blueprint: my nutrition and lifestyle framework.
Talk with me directly: start with a free 10-minute call, or book a full consultation.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Wada T, et al. A new thiamine derivative, S-benzoylthiamine O-monophosphate. Science. 1961;134(3473):195-196. doi:10.1126/science.134.3473.195
- Swissmedic. Public summary SwissPAR: milgamma (benfotiamine 300 mg). 2023. swissmedic.ch
- Thornalley PJ, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 2007;50:2164-2170. doi:10.1007/s00125-007-0771-4
- Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294-299. doi:10.1038/nm834
- Gibson GE, et al. Benfotiamine and cognitive decline in Alzheimer's disease: results of a randomized placebo-controlled phase IIa clinical trial. J Alzheimers Dis. 2020;78(3):989-1010. doi:10.3233/JAD-200896
- Manzardo AM, et al. Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug Alcohol Depend. 2013;133(2):562-570. doi:10.1016/j.drugalcdep.2013.07.035
- Haupt E, et al. Benfotiamine in the treatment of diabetic polyneuropathy: a three-week randomized, controlled pilot study (BEDIP). Int J Clin Pharmacol Ther. 2005;43:71-77. doi:10.5414/cpp43071
- Stracke H, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116:600-605. doi:10.1055/s-2008-1065351
- Stein J, et al. Association between neuropathy and B-vitamins: a systematic review and meta-analysis. Eur J Neurol. 2021;28:2054-2064. doi:10.1111/ene.14786
- Mandra EV, et al. Vitamin B supplementation for diabetic peripheral neuropathy: a review and meta-analysis. J Clin Med. 2026;15(13):5156. doi:10.3390/jcm15135156
- Ziegler D. Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Res Clin Pract. 2023;206 Suppl 1:110764. doi:10.1016/j.diabres.2023.110764
- Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy (BOND study). BMJ Open Diabetes Res Care. 2026;14:e005773. doi:10.1136/bmjdrc-2025-005773
- Fraser DA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care. 2012;35:1095-1097. doi:10.2337/dc11-1895
- Xie F, et al. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. J Clin Pharmacol. 2014;54(6):688-695. doi:10.1002/jcph.261
- Park WS, et al. Comparative pharmacokinetic analysis of thiamine and its phosphorylated metabolites administered as multivitamin preparations. Clin Ther. 2016;38(10):2277-2285. doi:10.1016/j.clinthera.2016.08.009
- Kiew KK, et al. Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics. Malays J Med Sci. 2002;9(1):21-27. PMID 22969314
- Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Chapter 4: Thiamin. National Academies Press; 1998. NBK114331
- BenfoTeam: a phase 2A/2B randomized trial of benfotiamine in early Alzheimer's disease. ClinicalTrials.gov NCT06223360
About the Author
Dr. Michael Fitzmaurice is a fellowship-trained peripheral nerve surgeon with a background in nerve physiology, metabolic health, and applied exercise physiology. Through years of surgical practice, he has observed the close relationship between metabolic health, cellular energy production, and nervous system function. His work focuses on how physical activity, recovery biology, and nutrition-informed strategies relate to long-term nerve and metabolic health.
He oversees Dr. Fitz Nutrition, an education-first initiative translating evidence-informed research into thoughtfully designed formulations for nerve and metabolic health, and believes that patients who understand the science make better decisions about their care.
This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always consult a qualified healthcare provider regarding your individual medical situation.